Ovarian Cancer

Clinical Trials

Below is a list of ovarian cancer clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation. (Each trial listed opens in a new window.)

Relapsed/Recurrent Disease

Trial of Intraperitoneal Administration of a CEA-Expressing Derivative Manufactured from a Genetically Engineered Strain of Measles Virus in Patients with Recurrent Ovarian Cancer (MC0117)
The purpose of this research study is:

• to learn the highest dose of a modified measles virus that can be given in the abdominal cavity of patients with recurrent ovarian cancer by using escalating doses of the virus in consecutive groups of patients without causing unacceptable side effects;
• to look at the side effects of the virus when administered in the abdominal cavity; and,
• to assess the virus' effects in the body using blood, urine, throat gargle specimen(s), and tissue samples.

The virus used in this study produces an active protein marker called CEA when it propagates. CEA is a protein, which is found in the blood of people with a variety of diseases, most notably cancer, and it has not been reported to cause disease. The longterm effects of inducing CEA in the blood are unknown. CEA can be measured in blood and used to follow the activity of the virus. MV-CEA is an investigational agent. It is not yet approved by the Food and Drug Administration (FDA) for treatment of cancer.
Read more.

Flavopiridol and Cisplatin in Advanced Epithelial Ovarian and Primary Peritoneal Cancers (MC0261)
This research study is being done to learn the effects (good and bad) of the drugs flavopiridol and cisplatin when given together to patients with ovarian and primary peritoneal cancer.
Read more.

Chemotherapy Treatment Trial using Lapatinib (Tykerb) and Topotecan (Hycamtin) for Patients with Platinum Resistant Ovarian or Primary Peritoneal Cancer
Treatment with topotecan has been shown to work against platinum-resistant ovarian cancer. The study drug lapatinib has been shown to help other drugs do their job better. This study will look at taking both drugs together to see if the combination of drugs is more effective.
Read more.

New Diagnosis/No Prior Treatment

Chemotherapy, Carboplatin and Paclitaxel (Taxol), and a Monoclonal Antibody, Bevacizumab (Avastin) for Women Newly Diagnosed or Having Received No Prior Treatment for Advanced Ovarian and Peritoneal Primary Cancer
This study is being done to compare the effects, good and bad, of the combination of carboplatin, paclitaxel, and Bevacizumab to the standard combination of carboplatin and paclitaxel alone on patients and the cancer.
Read more.

Quality of Life Study about Religious and Spiritual Activities Used as Coping Resources for Women with Advanced Ovarian, Primary Peritoneal, Fallopian Tube, or Early Stage Endometrial Cancer
More research is indicated to discover the true nature of the spiritual needs and concerns of women with newly diagnosed ovarian, primary peritoneal or fallopian tube cancer, or early stage endometrial cancer.
Read more.

Screening/Prevention

Ovarian Cancer Screening
This study is being done to look for molecular markers present in blood to distinguish benign (non-cancerous) ovarian tumors from ovarian cancer.
Read more.

Phase I Trials

A Phase I Study of Aminoflavone (AFP464) for the Treatment of Cancer
This study is being done to:

• Test the safety of a drug called Aminoflavone (AFP464) and see what effects (good and bad) it has on patients with solid tumors;
• Find the highest dose of AFP464 that can be given without causing bad side effects; and to
• Learn how the body handles or processes the drug.

Read more.

Trial of OSI-774 and CPT-11 to Treat Advanced Solid Tumors (MC0112)
This study is being done to find the highest safe dose of the two cancer drugs that can be given on a 3-week schedule. Researchers also want to learn about the side effects of OSI-774 and CPT-11 when they are given together and about the drug's effects in the body.
Read more.

A Phase I Study of XL647 for the Treatment of Cancer
This study is being done to:

• Find the highest dose of the cancer drug XL647 that can be given to patients with solid tumors without causing bad side effects;
• Learn about the side effects (good and bad) of XL647, and
• Learn how the body handles or processes XL647 and other effects in the body by analyzing blood samples collected from participants.

XL647 is an investigational drug that has not been approved by the Food and Drug Administration (FDA), or any other regulatory agency, and use in this study is investigational.
Read more.